Quantification of α1-fetoprotein mRNA in peripheral blood and bone marrow:: a tool for perioperative evaluation of patients with hepatocellular carcinoma

被引:18
作者
Aselmann, H
Wolfes, H
Rohde, F
Frerker, M
Deiwick, A
Jäger, MD
Klempnauer, J
Schlitt, HJ
机构
[1] Hannover Med Sch, Klin Viszeral & Transplantat Chirurg, D-30623 Hannover, Germany
[2] Hannover Med Sch, Inst Biophys Chem, Hannover, Germany
关键词
alpha(1)-fetoprotein; perioperative evaluation; hepatocellular carcinoma;
D O I
10.1007/s004230000199
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background/aims: Quantification of alpha (1)-fetoprotein (AFP) mRNA in the blood using reverse transcriptase polymerase chain reaction (RT-PCR) could be a useful tool in monitoring the dynamics of minimal residual disease in patients with hepatocellular carcinoma (HCC). Since all available assays do not take into account the efficiency of cell separation, RNA extraction and reverse transcription, a competitive RT-PCR assay for quantification of AFP mRNA in relation to the housekeeping gene glyceraldehyde phosphate dehydrogenase (GAPBH) was established. Patients and methods Peripheral blood of 22 patients and bone marrow aspirates of ii patients with hepatocellular carcinoma was monitored perioperatively. Eighteen patients with other hepatic rumours or non-malignant hepatic diseases rind 26 healthy blood donors served as controls. Messenger RNA contents were calculated relative to the content of GAPBH mRNA as an indicator of total cell count, Results: Among HCC patients, 6 of 22 (26%) were positive for AFP mRNA before operation with values ranging fi am 2 ag/100 fg to 36 ag/100 fg GAPDH mRNA (mean 14). Among. bone mal row samples, AFP mRNA was detectable in 5 of 11 (45%) cases, with 1 ag/100 fg to 23 ag/100 fg GAPDH (mean ?). However. AFP mRNA was also detectable in 3 of 18 (17%) control patients and in 2 of 26 (8%) healthy blood donors. Perioperative findings were highly variable. Conclusion: AFP mRNA is not a specific marker for circulating malignant hepatocytes. Whether definition of a cut-off level or the use of a multimarker-PCR will provide more useful data remains to be established.
引用
收藏
页码:118 / 123
页数:6
相关论文
共 29 条
[1]  
Barbu V, 1997, HEPATOLOGY, V26, P1171
[2]   ILLEGITIMATE TRANSCRIPTION - TRANSCRIPTION OF ANY GENE IN ANY CELL TYPE [J].
CHELLY, J ;
CONCORDET, JP ;
KAPLAN, JC ;
KAHN, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (08) :2617-2621
[3]   SINGLE-STEP METHOD OF RNA ISOLATION BY ACID GUANIDINIUM THIOCYANATE PHENOL CHLOROFORM EXTRACTION [J].
CHOMCZYNSKI, P ;
SACCHI, N .
ANALYTICAL BIOCHEMISTRY, 1987, 162 (01) :156-159
[4]   Quantitative analysis of alpha-fetoprotein mRNA in circulating peripheral blood of patients with hepatocellular and alphafetoprotein-producing gastric carcinomas [J].
Funaki, NO ;
Tanaka, J ;
Imamura, M .
LIFE SCIENCES, 1998, 62 (21) :1973-1984
[5]   Perioperative change in albumin messenger RNA levels in patients with hepatocellular carcinoma [J].
Gion, T ;
Taketomi, A ;
Shimada, M ;
Shirabe, K ;
Hasegawa, H ;
Takenaka, K ;
Sugimachi, K .
HEPATOLOGY, 1998, 28 (06) :1663-1668
[6]   ALBUMIN MESSENGER-RNA AS A MARKER OF CIRCULATING HEPATOCYTES IN HEPATOCELLULAR-CARCINOMA [J].
HILLAIRE, S ;
BARBU, V ;
BOUCHER, E ;
MOUKHTAR, M ;
POUPON, R .
GASTROENTEROLOGY, 1994, 106 (01) :239-242
[7]   VARIATION OF GROWTH-RATE OF A RAT-TUMOR DURING A LIGHT-DARK CYCLE - CORRELATION WITH CIRCADIAN FLUCTUATIONS IN TUMOR BLOOD-FLOW [J].
HORI, K ;
ZHANG, QH ;
LI, HC ;
SAITO, S .
BRITISH JOURNAL OF CANCER, 1995, 71 (06) :1163-1168
[8]   DETECTION OF LIVER-CELLS IN PERIPHERAL-BLOOD OF PATIENTS WITH ADVANCED-STAGE HEPATOCELLULAR-CARCINOMA [J].
KAR, S ;
CARR, BI .
HEPATOLOGY, 1995, 21 (02) :403-407
[9]   Detection of isolated disseminated tumor cells in bone marrow and blood samples of patients with hepatocellular carcinoma [J].
Kienle, P ;
Weitz, J ;
Klaes, R ;
Koch, M ;
Benner, A ;
Lehnert, T ;
Herfarth, C ;
Doeberitz, MV .
ARCHIVES OF SURGERY, 2000, 135 (02) :213-218
[10]   The functional relevance of passenger leukocytes and microchimerism for heart allograft acceptance in the rat [J].
Ko, S ;
Deiwick, A ;
Jäger, MD ;
Dinkel, A ;
Rohde, F ;
Fischer, R ;
Tsui, TY ;
Rittmann, KL ;
Wonigeit, K ;
Schlitt, HJ .
NATURE MEDICINE, 1999, 5 (11) :1292-1297